MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/tlcr-2026-0711

Медицинская библиотека · Translational lung cancer research · 2026

Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC.

Collazo-Lorduy Ana, Calvo Virginia, Nadal Ernest, Provencio Mariano

СтатьяПеревод пока не подготовлен

Аннотация

Reducing postoperative recurrence remains an unmet need in locally advanced non-small-cell lung cancer (NSCLC), particularly in patients with epidermal growth factor receptor (EGFR)-mutated tumours, who are at higher risk of distant metastases after surgery; particularly brain metastases. Perioperative and neoadjuvant chemoimmunotherapy strategies have improved survival outcomes in unselected populations; however, the evidence in EGFR-mutated NSCLC remains limited because most pivotal trials-including NADIM, NADIM II, CheckMate 816, RATIONALE-315, CheckMate 77T and Neotorch-excluded patients with known EGFR mutations. This gap provides a rationale for exploring the use of anti-angiogenic agents combined with chemoimmunotherapy in a molecular subgroup that is usually less-immunoresponsive. While this strategy has demonstrated efficacy in the metastatic EGFR-mutated setting, as reported in IMpower150, ATTLAS/KCSG-LU19-04 or ORIENT-31 study, prospective evidence in resectable disease is lacking. The Neo-DIANA trial was a multicentre, open-label, non-randomised phase II clinical trial designed to investigate a neoadjuvant regimen combining atezolizumab, chemotherapy and bevacizumab, followed by surgery and adjuvant atezolizumab, in resectable stages IIIA and IIIB EGFR-mutated NSCLC. Because the trial was terminated early due to slow recruitment, no conclusions can be drawn regarding the efficacy of combination therapy in patients with resectable EGFR-mutated NSCLC. Further studies are still needed to explore perioperative strategies that may help reduce postoperative relapses in these patients.

Для цитирования: Collazo-Lorduy Ana, Calvo Virginia, Nadal Ernest, Provencio Mariano. Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC.. Translational lung cancer research. 2026. DOI: 10.21037/tlcr-2026-0711.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.